Skip to main content

Funding round · 2026-11-11 · Healthcare

VectorY Therapeutics raises $80.5M

68
AI Score
Amount
$80.5M
Round
Undisclosed
Lead
Not disclosed
HQ
Amsterdam, NL
Why it matters: The round shows which investors are backing AAV-delivered antibody therapies for ALS and Huntington's, and where the lead program stands in its Phase 1/2 trial.

VectorY Therapeutics, an Amsterdam biotech, raised €74.5M ($83.5M) from new investors including Angelini Ventures.

Participants:
Angelini Ventures, Invest-NL, European Investment Bank, Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BGV, Eli Lilly and Company, ALS Investment Fund

Deal Dossier PRO

Pro feature
Deal Dossier for VectorY Therapeutics

Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.

Generate dossier — Pro
Already Pro? Sign in · See plans

Figures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).

Recent Healthcare rounds

Browse all deals in the funding database →

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing